Vabiotech Licenses Japanese Encephalitis Technology From Inviragen
Vietnam’s VABIOTECH has acquired rights to Inviragen’s proprietary Japanese encephalitis technology to produce a cell-derived vaccine.
AsianScientist (Jan. 7, 2013) – The Company for Vaccine and Biological Production No.1 (VABIOTECH) has acquired rights to Inviragen’s proprietary Japanese encephalitis (JE) technology to produce a cell-derived vaccine.
Under the terms of the agreement, VABIOTECH may exclusively develop and commercialize JE vaccine based on Inviragen’s cell-based technology in Vietnam, Cambodia, and Myanmar. In exchange, Inviragen will receive certain development-based milestone payments from VABIOTECH.
“The technology licensed from Inviragen will help advance our JE vaccine production technology,” said Professor Dr. Nguyen Thu Van, director general of the Company.
“In partnership with the Ministry of Health, we have made great strides to control the spread of JE infection in Vietnam. We look forward to incorporating this vaccine technology from Inviragen into our JE program.”
VABIOTECH was established as a State-owned Company by the Vietnamese Minister of Health in 2000. In 2007, VABIOTECH was spun off from the National Institute of Hygiene and Epidemiology as an independent company under the Ministry of Health of Vietnam.
The World Health Organization (WHO) estimates that there are 68,000 severe clinical cases of JE annually in Asia, causing 10,000 to 15,000 deaths per year.
Source: Inviragen; Photo: Sanofi-Pasteur/Flickr/CC.
Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.